Literature DB >> 17033617

Diabetes and the risk of prostate cancer: the role of diabetes treatment and complications.

C M Velicer1, S Dublin, E White.   

Abstract

Epidemiologic evidence suggests diabetic men have a slightly lower prostate cancer risk than non-diabetic men. We examined this association in a prospective cohort study of 35 239 men, 50-76 years old, in Washington State who completed a baseline questionnaire between 2000 and 2002. Incident prostate cancers as of 31 December 2004 were identified through the SEER registry. Diabetic men had a slightly lower risk of prostate cancer than non-diabetic men (hazard ratio (HR) 0.83, 95% confidence interval (CI) 0.64-1.07). Insulin users overall and insulin users with diabetic complications had decreased risks, compared to non-diabetic men (HR 0.49, 95% CI 0.26-0.92) and (HR 0.36, 95% CI 0.15-0.87), respectively. Oral medication use for diabetes was not associated with prostate cancer. Insulin is likely a marker of severity of diabetes. Future studies of this association should consider diabetes type, treatment, severity, complications and biomarkers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17033617     DOI: 10.1038/sj.pcan.4500914

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  9 in total

1.  HNF1B and JAZF1 genes, diabetes, and prostate cancer risk.

Authors:  Victoria L Stevens; Jiyoung Ahn; Juzhong Sun; Eric J Jacobs; Steven C Moore; Alpa V Patel; Sonja I Berndt; Demetrius Albanes; Richard B Hayes
Journal:  Prostate       Date:  2010-05-01       Impact factor: 4.104

2.  Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

Authors:  X-X He; S M Tu; M-H Lee; S-C J Yeung
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

3.  A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).

Authors:  Ali S Murad; George Davey Smith; Sarah J Lewis; Angela Cox; Jenny L Donovan; David E Neal; Freddie C Hamdy; Richard M Martin
Journal:  Int J Mol Epidemiol Genet       Date:  2010-04-01

4.  Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study.

Authors:  Gabriel Y Lai; Kathy J Helzlsouer; Sandra L Clipp; Nader Rifai; Elizabeth A Platz
Journal:  Cancer Prev Res (Phila)       Date:  2010-09-21

Review 5.  Defining the molecular nexus of cancer, type 2 diabetes and cardiovascular disease.

Authors:  S M Cabarcas; E M Hurt; W L Farrar
Journal:  Curr Mol Med       Date:  2010-11       Impact factor: 2.222

6.  Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study.

Authors:  Jocelyn S Kasper; Yan Liu; Edward Giovannucci
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

7.  Association of diabetes with prostate cancer risk in the multiethnic cohort.

Authors:  Kevin M Waters; Brian E Henderson; Daniel O Stram; Peggy Wan; Laurence N Kolonel; Christopher A Haiman
Journal:  Am J Epidemiol       Date:  2009-02-24       Impact factor: 4.897

Review 8.  CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis.

Authors:  Jakob Starup-Linde; Oystein Karlstad; Stine Aistrup Eriksen; Peter Vestergaard; Heleen K Bronsveld; Frank de Vries; Morten Andersen; Anssi Auvinen; Jari Haukka; Vidar Hjellvik; Marloes T Bazelier; Anthonius de Boer; Kari Furu; Marie L De Bruin
Journal:  Curr Drug Saf       Date:  2013-11

9.  Association of obesity and diabetes with serum prostate-specific antigen levels in Japanese males.

Authors:  Mariko Naito; Yatami Asai; Atsuyoshi Mori; Yuko Fukada; Mayumi Kuwabara; Shiro Katase; Asahi Hishida; Emi Morita; Sayo Kawai; Rieko Okada; Kazuko Nishio; Akiko Tamakoshi; Kenji Wakai; Nobuyuki Hamajima
Journal:  Nagoya J Med Sci       Date:  2012-08       Impact factor: 1.131

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.